Myeloid Differentiation Factor 88
"Myeloid Differentiation Factor 88" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An intracellular signaling adaptor protein that plays a role in TOLL-LIKE RECEPTOR and INTERLEUKIN 1 RECEPTORS signal transduction. It forms a signaling complex with the activated cell surface receptors and members of the IRAK KINASES.
| Descriptor ID |
D053594
|
| MeSH Number(s) |
D12.644.360.024.311 D12.776.157.057.074 D12.776.476.024.390
|
| Concept/Terms |
Myeloid Differentiation Factor 88- Myeloid Differentiation Factor 88
- Toll-Like Receptor Signal Adaptor Protein MyD88
- Toll Like Receptor Signal Adaptor Protein MyD88
- MyD88 Protein
- TLR Signal Adaptor Protein MyD88
|
Below are MeSH descriptors whose meaning is more general than "Myeloid Differentiation Factor 88".
Below are MeSH descriptors whose meaning is more specific than "Myeloid Differentiation Factor 88".
This graph shows the total number of publications written about "Myeloid Differentiation Factor 88" by people in this website by year, and whether "Myeloid Differentiation Factor 88" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2004 | 0 | 1 | 1 |
| 2006 | 0 | 1 | 1 |
| 2007 | 0 | 1 | 1 |
| 2009 | 1 | 0 | 1 |
| 2010 | 2 | 2 | 4 |
| 2011 | 2 | 2 | 4 |
| 2012 | 1 | 2 | 3 |
| 2013 | 0 | 2 | 2 |
| 2014 | 1 | 2 | 3 |
| 2015 | 2 | 2 | 4 |
| 2016 | 6 | 3 | 9 |
| 2017 | 3 | 3 | 6 |
| 2018 | 2 | 5 | 7 |
| 2019 | 3 | 4 | 7 |
| 2020 | 4 | 5 | 9 |
| 2021 | 5 | 3 | 8 |
| 2022 | 1 | 4 | 5 |
| 2023 | 0 | 1 | 1 |
| 2024 | 0 | 1 | 1 |
| 2025 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Myeloid Differentiation Factor 88" by people in Profiles.
-
Lasalocid A selectively induces the degradation of MYD88 in lymphomas harboring the MYD88 L265P mutation. Blood. 2025 Mar 06; 145(10):1047-1060.
-
PSCA-targeted BPX-601 CAR T cells with pharmacological activation by rimiducid in metastatic pancreatic and prostate cancer: a phase 1 dose escalation trial. Nat Commun. 2024 Dec 30; 15(1):10743.
-
The RNA receptor RIG-I binding synthetic oligodeoxynucleotide promotes pneumonia survival. JCI Insight. 2024 Nov 08; 9(21).
-
From the archives of MD Anderson Cancer Center: Composite mantle cell lymphoma and lymphoplasmacytic lymphoma involving bone marrow at presentation. Ann Diagn Pathol. 2024 Dec; 73:152372.
-
Biomarker analysis of the ASPEN study comparing zanubrutinib with ibrutinib for patients with Waldenstr?m macroglobulinemia. Blood Adv. 2024 04 09; 8(7):1639-1650.
-
Therapeutic effect of Echinococcus granulosus cyst fluid on bacterial sepsis in mice. Parasit Vectors. 2023 Dec 08; 16(1):450.
-
Effect of epithelial-specific MyD88 signaling pathway on airway inflammatory response to organic dust exposure. J Immunotoxicol. 2023 12; 20(1):2148782.
-
Toll-like receptors 2, 4, and 9 modulate promoting effect of COPD-like airway inflammation on K-ras-driven lung cancer through activation of the MyD88/NF-?B pathway in the airway epithelium. Front Immunol. 2023; 14:1118721.
-
Improving the anti-acute myeloid leukemia activity of CD123-specific engager T cells by MyD88 and CD40 costimulation. Haematologica. 2023 04 01; 108(4):1039-1052.
-
Clinicopathologic Features and Genomic Signature of De Novo CD5 + Diffuse Large B-Cell Lymphoma : A Multicenter Collaborative Study. Am J Surg Pathol. 2022 11 01; 46(11):1533-1544.